55
Participants
Start Date
August 31, 2011
Primary Completion Date
October 31, 2016
Study Completion Date
December 31, 2016
Lenalidomide
All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
National Taiwan University Hospital, Taipei
National Taiwan University Hospital
OTHER